Table 3 presents the sensitivity, cutoff value, and patient stage distribution in 11 studies [17, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50] that analyzed groups of 100–1000 patients with gastric cancer, simultaneously measuring four blood‐based tumor markers (CEA, CA19‐9, CA72‐4, and CA125). This evidence concerns the gene CEACAM5 and neoplasm.